BCMA-GPRC5D CAR-T
/ Hedy Group
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 30, 2025
BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Guangzhou Bio-gene Technology Co., Ltd
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
September 27, 2025
r/r MM: Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment
(clinicaltrials.gov)
- P=N/A | N=10 | Not yet recruiting | Sponsor: Guangzhou Bio-gene Technology Co., Ltd
New trial • Hematological Malignancies • Multiple Myeloma • Oncology
July 23, 2024
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
(clinicaltrials.gov)
- P=N/A | N=10 | Recruiting | Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
CAR T-Cell Therapy • New trial • Hematological Malignancies • Multiple Myeloma • Oncology
August 21, 2023
BCMA-GPRC5D CAR-T Cells for Multiple Myeloma
(clinicaltrials.gov)
- P2 | N=10 | Recruiting | Sponsor: Wuhan Union Hospital, China
CAR T-Cell Therapy • IO biomarker • New P2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 4
Of
4
Go to page
1